Liver injury in COVID-19: two clinical cases

COVID-19 (coronavirus disease 2019, a  disease caused by a  new coronavirus 2019) continues to threaten world public healthcare. Epidemiological data indicate that patients with metabolic disorders and chronic illnesses are most susceptible to SARS-CoV-2 (severe acute respiratory syndrome coronaviru...

Full description

Bibliographic Details
Main Authors: I. G. Nikitin, L. Yu. Ilchenko, I. G. Fedorov, G. G. Totolyan
Format: Article
Language:Russian
Published: MONIKI 2020-12-01
Series:Alʹmanah Kliničeskoj Mediciny
Subjects:
Online Access:https://www.almclinmed.ru/jour/article/view/1369
_version_ 1818571584494895104
author I. G. Nikitin
L. Yu. Ilchenko
I. G. Fedorov
G. G. Totolyan
author_facet I. G. Nikitin
L. Yu. Ilchenko
I. G. Fedorov
G. G. Totolyan
author_sort I. G. Nikitin
collection DOAJ
description COVID-19 (coronavirus disease 2019, a  disease caused by a  new coronavirus 2019) continues to threaten world public healthcare. Epidemiological data indicate that patients with metabolic disorders and chronic illnesses are most susceptible to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Potential factors for organ involvement include systemic hyperimmune-mediated inflammation due to the “cytokine storm”, cytopathic effects, hypoxia, drug toxicities, etc. In addition, SARS-CoV-2, by interaction with ACE2 (angiotensin-converting enzyme 2) receptors in the vasculature endothelium results in endothelial dysfunction, increased permeability, microcirculatory abnormalities, vascular thrombophilia and thrombus formation. The diagnosis of COVID-19 is confirmed by detection of SARS-CoV-2 RNA in biological samples and serum antibodies. The infection is associated with leukopenia and thrombocytopenia, increased С-reactive protein, ferritin, lactate dehydrogenase, and D-dimer. Abnormalities in functional liver tests seen in COVID-19 are associated with progression and severity of the infection. The mechanism of direct cytotoxicity due to active SARS-CoV-2 replication in hepatocytes are not fully understood and is likely to be related to potential proliferation of hepatocytes, liver injury in response to systemic inflammation, and development of drug hepatic toxicity. We present a  clinical case of drug-induced hepatitis in a  patient with COVID-19 treated with tocilizumab, an inhibitor of interleukin 6 receptors. Prolonged increase in blood enzymes after treatment cessation is likely related to a  longer half-elimination time of tocilizumab, which affects the oxidation-reduction system of liver cytochromes. Patients with chronic liver disorders are more vulnerable to clinical sequelae of СOVID-19, while the infection is frequently associated with hypoxia and hypoxemia due to severe pneumonia or the “cytokine storm”. In addition, patients who have been diagnosed with liver cirrhosis are at high risk of morbidity and mortality due to their higher proneness to infections, first of all, due to systemic immune deficiency that was demonstrated in the second clinical case. Decompensated liver cirrhosis is related not only to a higher risk of more severe COVID-19, but also to progression of chronic liver disease as such. To achieve effective results of causal and nosotropic therapy for COVID-19, it is highly significant to provide thorough clinical monitoring, tailored approach to the treatment of each patient with consideration of their comorbidities, immune status, and drug interactions.
first_indexed 2024-12-14T13:57:55Z
format Article
id doaj.art-be8d0ae8d03244e08cf9f67d022fc8b6
institution Directory Open Access Journal
issn 2072-0505
2587-9294
language Russian
last_indexed 2024-12-14T13:57:55Z
publishDate 2020-12-01
publisher MONIKI
record_format Article
series Alʹmanah Kliničeskoj Mediciny
spelling doaj.art-be8d0ae8d03244e08cf9f67d022fc8b62022-12-21T22:58:48ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942020-12-0148641242110.18786/2072-0505-2020-48-053752Liver injury in COVID-19: two clinical casesI. G. Nikitin0L. Yu. Ilchenko1I. G. Fedorov2G. G. Totolyan3Pirogov Russian National Research Medical University (RNRMU); Centre of Medical RehabilitationPirogov Russian National Research Medical University (RNRMU); Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences; I.I. Mechnikov Scientific Research Institute of Vaccines and SerumsPirogov Russian National Research Medical University (RNRMU); Moscow City Clinical Hospital after V.M. BuyanovPirogov Russian National Research Medical University (RNRMU)COVID-19 (coronavirus disease 2019, a  disease caused by a  new coronavirus 2019) continues to threaten world public healthcare. Epidemiological data indicate that patients with metabolic disorders and chronic illnesses are most susceptible to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Potential factors for organ involvement include systemic hyperimmune-mediated inflammation due to the “cytokine storm”, cytopathic effects, hypoxia, drug toxicities, etc. In addition, SARS-CoV-2, by interaction with ACE2 (angiotensin-converting enzyme 2) receptors in the vasculature endothelium results in endothelial dysfunction, increased permeability, microcirculatory abnormalities, vascular thrombophilia and thrombus formation. The diagnosis of COVID-19 is confirmed by detection of SARS-CoV-2 RNA in biological samples and serum antibodies. The infection is associated with leukopenia and thrombocytopenia, increased С-reactive protein, ferritin, lactate dehydrogenase, and D-dimer. Abnormalities in functional liver tests seen in COVID-19 are associated with progression and severity of the infection. The mechanism of direct cytotoxicity due to active SARS-CoV-2 replication in hepatocytes are not fully understood and is likely to be related to potential proliferation of hepatocytes, liver injury in response to systemic inflammation, and development of drug hepatic toxicity. We present a  clinical case of drug-induced hepatitis in a  patient with COVID-19 treated with tocilizumab, an inhibitor of interleukin 6 receptors. Prolonged increase in blood enzymes after treatment cessation is likely related to a  longer half-elimination time of tocilizumab, which affects the oxidation-reduction system of liver cytochromes. Patients with chronic liver disorders are more vulnerable to clinical sequelae of СOVID-19, while the infection is frequently associated with hypoxia and hypoxemia due to severe pneumonia or the “cytokine storm”. In addition, patients who have been diagnosed with liver cirrhosis are at high risk of morbidity and mortality due to their higher proneness to infections, first of all, due to systemic immune deficiency that was demonstrated in the second clinical case. Decompensated liver cirrhosis is related not only to a higher risk of more severe COVID-19, but also to progression of chronic liver disease as such. To achieve effective results of causal and nosotropic therapy for COVID-19, it is highly significant to provide thorough clinical monitoring, tailored approach to the treatment of each patient with consideration of their comorbidities, immune status, and drug interactions.https://www.almclinmed.ru/jour/article/view/1369sars-cov-2covid-19liver injuryclinical cases
spellingShingle I. G. Nikitin
L. Yu. Ilchenko
I. G. Fedorov
G. G. Totolyan
Liver injury in COVID-19: two clinical cases
Alʹmanah Kliničeskoj Mediciny
sars-cov-2
covid-19
liver injury
clinical cases
title Liver injury in COVID-19: two clinical cases
title_full Liver injury in COVID-19: two clinical cases
title_fullStr Liver injury in COVID-19: two clinical cases
title_full_unstemmed Liver injury in COVID-19: two clinical cases
title_short Liver injury in COVID-19: two clinical cases
title_sort liver injury in covid 19 two clinical cases
topic sars-cov-2
covid-19
liver injury
clinical cases
url https://www.almclinmed.ru/jour/article/view/1369
work_keys_str_mv AT ignikitin liverinjuryincovid19twoclinicalcases
AT lyuilchenko liverinjuryincovid19twoclinicalcases
AT igfedorov liverinjuryincovid19twoclinicalcases
AT ggtotolyan liverinjuryincovid19twoclinicalcases